Latest long-term debt for CBPO: $0.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
China Biologic Products Holdings (CBPO) currently reports a long-term debt of $0 as of December 2020. In the prior-year period, the figure was $0. Use the charts on this page to explore China Biologic Products Holdings's long-term debt history and peer comparisons.
China Biologic Products Holdings's long-term debt changed from $0 to $0 (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
China Biologic Products Holdings reported $0 in long-term debt as of December 2020. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for China Biologic Products Holdings, and consider following CBPO for alerts when major investors trade the stock.
China Biologic Products Holdings is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBPO with unrelated industries.